Please assess the completion status of the following clinical trial:

Trial Title: The Effects of Cannabis Use in People With Schizophrenia on Clinical, Neuropsychological and Physiological Phenotypes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male and females~* 18 and 50 years of age~* Diagnosis of schizophrenia~* Chronic cannabis users who have used for at least 1 year~* Using cannabis at least once weekly~* Currently being treated with antipsychotic medication~* Must be on a the same dose of antipsychotic medication for at least 3 months.~* Females of childbearing potential must use an adequate form of birth control while participating.~* Participants will be required to have blood pressures greater than 90/60 and less than 140/90.~Exclusion Criteria:~* Use of illicit drugs other than cannabis~* Any psychiatric hospitalizations within 3 months~* pregnancy in females~* taking clozapine

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: f

Study Arms:
- dronabinol (Type: ACTIVE_COMPARATOR): dronabinol 10 mg one capsule by mouth at 8:00 a.m.
- sugar pill (Type: PLACEBO_COMPARATOR): one capsule given by mouth at 8:00 a.m.

Based on this trial design, predict the completion outcome and termination type (if applicable).